ALK and anaplastic large cell lymphoma: ML162 (a GPX4 inhibitor) treatment in FDFT1‐deficient ALK+ ALCL (ALK+ anaplastic large cell lymphoma) cells depleted squalene, damaging membrane PUFAs, key ferroptosis drivers, and generating lipid peroxides that induced ferroptosis [132].